Past News Items - March 2024

In the News

The Institute for Functional Medicine (IFM) is pleased to announce the appointment of Gail C. Christopher, DN, (Chair) David S. Jones, MD (Vice-Chair), David Harris, BFA (Secretary), and Terry L. Cook, CFP®, CIMA® (Treasurer) to serve as Board Officers for a two-year term, January 2024-December 2025.

Pusan National University Researchers Reveal How Diabetes Weakens Gum Defense

New clinical trial shows that algae-based omega-3 lecithin AlmegaPL® provides better cardiovascular health support compared to traditional omega-3 fish oils

New SANOIN Study Findings show Significant Rise in Hb levels in 14 days, Symptom Relief in 30 days & Improved Quality of life in women with Iron Deficiency Anemia

New Study Publication Demonstrates Eye Health and Cognitive Benefits of Lutein and Zeaxanthin from Lutemax Kids

Gnosis Introduces Ethically Sourced Natural Energy & Mood Innovation: LANDKIND® Pure Salidroside

The Institute for Functional Medicine (IFM) is pleased to announce the appointment of Gail C. Christopher, DN, (Chair) David S. Jones, MD (Vice-Chair), David Harris, BFA (Secretary), and Terry L. Cook, CFP®, CIMA® (Treasurer) to serve as Board Officers for a two-year term, January 2024-December 2025.

IFM’s governing Board of Directors brings stewardship, insight, expertise, and resources to advance the organization’s mission to ensure the widespread adoption of functional medicine. This volunteer board provides guidance to IFM’s executive leadership and offers strategic support for the organization to ensure advancement of health and well-being for all.

“I am honored to welcome Dr. Gail Christopher as Chair of the IFM Board of Directors and to work with this distinguished group of board officers,” celebrates IFM Chief Executive Officer, Amy R. Mack, MSES/MPA. “The strategic support and direction provided by the board is critically important as we work to further enhance our education and training, elevate the certification program, build and strengthen partnerships, and explore new opportunities to drive systemic change in the delivery of healthcare around the globe.”

IFM is deeply grateful to outgoing board chair, Joseph E. Pizzorno, ND, for his experience and leadership. Serving the last two consecutive terms, Dr. Pizzorno helped guide the organization through the COVID-19 pandemic, expand collaborations and strategic partnerships, champion practitioners throughout the military and Veterans Health Administration, and many other notable accomplishments.

“Dr. Pizzorno’s work will continue to positively impact IFM and the field of functional medicine, and I am honored to build on all he has contributed to this organization,” shares Gail C. Christopher, DN. “Looking ahead, IFM is poised to fundamentally transform the way functional medicine is understood, practiced, and embraced for all populations. I am thrilled to serve as chair during this exciting era.”

IFM Board Officers:

Gail C. Christopher, DN Chair: Dr. Gail Christopher, an award-winning social change agent, is known for her pioneering work to infuse holistic health and diversity concepts into public sector programs and policy discourse. Dr. Christopher recently retired from her role as Senior Advisor and Vice President at the W.K. Kellogg Foundation, where she was the driving force behind the America Healing initiative and the Truth, Racial Healing and Transformation effort. In August 2017, Dr. Christopher left her position to launch the Maryland-based Ntianu Center for Healing and Nature and to devote more time to writing and speaking on issues of health, racial healing, and human capacity for caring.

David S. Jones, MD Vice-Chair: Serving as IFM President from 1999 to 2013, Dr. David Jones guided the organization in the clinical development of functional medicine. Under Dr. Jones’ leadership and guidance, IFM became a freestanding, independent, 501(c)(3) nonprofit and ACCME-accredited educational institute—a change that enabled the organization to focus entirely on its premier educational mission, free of any commercial influence.

David Harris, BFA Secretary: With a distinguished career focused on physical education and program development, David Harris brings a wealth of experience to IFM. As the Chief Officer of Innovation and Human Performance for FORME life and an Optimist for Simon Sinek, Inc., David’s expertise in the science of stimulus and adaptation, and more than a decade of research collaboration uniquely positions him to contribute valuable insights to enhance the widespread adoption of functional medicine.

Terry L. Cook, CFP®, CIMA® Treasurer: 

For the last 25 years, Terry Cook has focused on financial planning and management for corporate executives, business owners and successful families. As founder of The Cascade Group and with a notable list of accomplishments and community leadership experience, Terry lends both his professional expertise and personal passion to IFM’s board of directors. A long-standing patient of functional medicine, he has witnessed firsthand the powerful transformation of a comprehensive, root cause approach.

Board terms have also been renewed for David Jones, Terry Cook, and Jeffrey Bland, PhD. Mark Hyman, MD, IFMCP, Loren Israelsen, JD, and Joseph E. Pizzorno, ND continue to serve as board members. Biographies for all board members can be found at IFM.org.

# # #

About The Institute for Functional Medicine (IFM)

As the leading voice for functional medicine for more than 30 years, The Institute for Functional Medicine is advancing the transformation of healthcare for patients and practitioners worldwide. IFM supports the confident and competent practice of functional medicine through high-quality education and certification programs; partnerships across medical disciplines; and advocating on behalf of functional medicine clinicians and patients around the globe. IFM is a 501(c)(3) nonprofit organization and the only organization providing functional medicine certification along with educational programs directly accredited by the Accreditation Council for Continuing Medical Education (ACCME). For more information, please visit IFM.org.

About Functional Medicine

As a catalyst in the transformation of healthcare, functional medicine treats root causes of disease and restores healthy function through a personalized patient experience. From chronic illness to disease prevention, functional medicine systematically addresses the unique physical, mental, and emotional needs of all patients. By understanding each patient’s genetic, environmental, and lifestyle influences, functional medicine is a vital partner to conventional medicine that delivers transformative care to promote optimal health and well-being.

For more information:

Alyssa Parker

Associate Director, Public Affairs

media@ifm.org

Pusan National University Researchers Reveal How Diabetes Weakens Gum Defense

Periodontitis (PD) is a common complication in individuals with diabetes mellitus (DM). Despite the profound implications for overall health, the complex bidirectional relationship between them lacks a comprehensive understanding so far, leaving the precise nature of their immunological connection inadequately understood. Prior studies focusing on local immune responses in gingival tissue fall short in capturing the systemic immunological relationship.

In an innovative study, researchers from the Republic of Korea have investigated the relationship between periodontitis (PD) and diabetes mellitus (DM). Led by Assistant Professor Yun Hak Kim from Pusan National University, the study employs pioneering single-cell RNA analysis and digs into the immune dynamics at the cellular level. This recent study was made available online on December 11, 2023, and was published in Volume 13, Issue 12 of the Clinical and Translational Medicine journal in December 2023. Dr. Kim says, "Our study promises to transform our understanding of the complex interplay between these two prevalent health conditions and sheds light on the systemic impact of these conditions, offering a potential avenue for targeted interventions."

But what exactly is this immunological link?

The study, conducted on a diverse group that included healthy individuals as well as patients with periodontitis (PD) and those with both PD and type 2 diabetes mellitus (PDDM), utilized single-cell RNA sequencing to explore the systemic immunological connections between PD and DM. The researchers methodically analyzed peripheral blood mononuclear cells by single cell RNA sequencing, revealing transcriptomic characteristics and cell interactions.

The study identified pro-inflammatory cytokines rise in classical monocytes in both PD and PDDM groups. Further analysis revealed the influence of DM on T lymphocyte counts. CD4+ effector T cells exhibited reduced activation under DM conditions, indicating a broader systemic impact on immune regulation. The compromised functions of CD8+ T cells and natural killer (NK) cells in the presence of both PD and DM further highlight the intricate immune changes occurring at the cellular level.

The RESISTIN pathway, known for its association with insulin resistance, was found to be intensified in both PD and PDDM groups, primarily involving classical monocytes. This discovery adds a crucial piece to the puzzle, suggesting a shared intercellular pathway that contributes to the complex PD-DM relationship. The discovery of RESISTIN in the blood of patients with periodontitis but without underlying diseases highlights its role in inflammation and its potential as a therapeutic target to reduce diabetes risk in patients with PD. The outcomes point to significant immune alterations in patients with both PD and DM, emphasizing the potential role of PD as a precursor to diabetes.

In conclusion, this groundbreaking research provides a first-of-its-kind immunological explanation for the complex association between periodontitis and type 2 diabetes mellitus. The use of single-cell RNA analysis has uncovered cellular-level immune changes, offering a new perspective on the systemic impact of these prevalent health conditions. The study not only advances our scientific understanding but also lays the foundation for potential interventions aimed at diminishing the risk and impact of diabetes in individuals with periodontitis!

Reference

Title of original paper: Immunological link between periodontitis and type 2 diabetes deciphered by single-cell RNA analysis

Journal: Clinical and Translational Medicine

DOI: https://doi.org/10.1002/ctm2.1503

New clinical trial shows that algae-based omega-3 lecithin AlmegaPL® provides better cardiovascular health support compared to traditional omega-3 fish oils

Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi life™, delivers clinically relevant results decreasing triglycerides by 14% and remnant cholesterol such as very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) by up to 25%.1,2  "This marks the second clinical trial endorsing the use of AlmegaPL® algal lecithin to support cardiovascular health in a generally healthy population," says Dr. Eneko Ganuza, a principal investigator who led the research.

The new clinical trial led by Dr. Ganuza and sponsored by Qualitas Health was initiated to uncover just how effective an over-the-counter supplement can be in supporting cardiovascular health in the real-world population. The findings support existing beliefs that EPA-only omega-3s like AlmegaPL® could provide greater cardiovascular benefits when compared to traditional sources of omega-3s like fish and krill oil that contain both EPA and DHA.

According to the World Health Organization, cardiovascular disease (CVD) continues to be the leading cause of death globally, with dietary factors, including inadequate intake of long-chain n-3 polyunsaturated fatty acids —specifically EPA and DHA—estimated to contribute to approximately half of all CVD- related deaths annually.3,4 With 95% of the U.S. population failing to consume an adequate amount of omega-3s, interest around DHA and EPA treatment has grown, launching a growing debate around their subsequent roles in cardiovascular support.5

In the cohort study, AlmegaPL® delivered in the form of the iwi life "Heart" supplement was clinically shown to decrease triglycerides by 14%, which is 4 times the response expected from other omega-3 sources.1 "While triglyceride levels within the normal range are typically beyond the scope of clinical intervention, they still retain a residual heart health risk," states Dr. Ganuza. "The study's significance is underscored by its execution within a real-world population, predominantly normolipidemic supplement consumers. This highlights the use of naturally sourced AlmegaPL® algal oil as an over-the-counter supplement to help support cardiovascular health in the general healthy population."

AlmegaPL® uses a proprietary strain of omega-3 fatty acid extracted from the photoautotrophic microalgae Nannochloropsis, which is now clinically confirmed by two independent studies to decrease remnant cholesterol by up to 25 %.1,2 Neither study resulted in an increase in LDL cholesterol, which is a unique benefit of EPA-only formulations, as studies using fish oil, which naturally contain both EPA and DHA, were shown to increase LDL cholesterol.6  This research demonstrates the powerful ability of EPA-only AlmegaPL® to outperform other omega-3 sources to support cardiovascular health.*

The CEO of iwi life, Tom Dimke, responded to the results stating that "integrating AlmegaPL® in iwi life products—an ingredient with such impressive clinical data supporting it—allows us to bring innovative and effective consumer-ready products to the market with confidence."

The triple patented microalgae technology of AlmegaPL® is the first and only commercially available photosynthetic source of long-chain omega fatty acids available for human consumption in the USA. The utilization of AlmegaPL® in supplements is not only clinically verified to have superior bioavailability but contains key phytonutrients and other natural antioxidants that protect the omega-3 against oxidation.7 According to Dr. Ganuza, "EPA is increasingly recognized as the primary long-chain omega fatty acids for supporting cardiovascular health, however, other natural marine sources of omega-3 fatty acids contain some level of DHA, except for AlmegaPL®," allowing AlmegaPL®  to stand out as the sole natural source of EPA-only omega-3 available over the counter to support cardiovascular health.

Although AlmegaPL® is not promoted to support healthy weight management, additional findings in the first clinical trial revealed that while there were no differences between groups for any anthropometry measure at the baseline, supplementation with AlmegaPL® for 12 weeks resulted in a decrease in hip circumference and body weight (adjusted for age and baseline BMI) compared to the placebo group, where hip circumference increased from the baseline at week 12.1

In discussing the outcomes, Dr. Ganuza says "The remarkable triglyceride-lowering response observed in this clinical trial cannot be solely attributed to the omega-3 content alone. There is something about the unique polar form in which this algal lecithin yields the omega-3s that prove highly beneficial to our heart health." AlmegaPL® utilizes sunlight to create a unique molecular form of omega-3 from the non-GMO microalgae Nannochloropsis with naturally occurring polar lipids that are readily dispersed into tiny droplets for easy absorption and utilization in our bodies and this improved efficacy allows for a smaller serving size to support healthy omega-3 levels.7

iwi life is an award-winning leader in nutrition innovation, providing consumers with a range of bioavailable, vegan omega-3 supplements derived from sustainably USA-grown algae. For more information about their brand and products, visit iwilife.com. For media-related inquiries, please contact tgriffin@iwilife.com.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

References:

Rao et al., 2020 Nutrients.

Ganuza et al., 2024 Front Nutr. 

World Health Organization, 2021 Cardiovascular Diseases Fact Sheet.

Micha, Renata et al., 2017 JAMA.

Murphy R.A. et al.,  2015 Nutrients.

Eslick et al., 2009 Int J Cardiol

Kagan et al., 2013 Lipids Health Dis.

SOURCE Qualitas Health (dba iwi life)

New SANOIN Study Findings show Significant Rise in Hb levels in 14 days, Symptom Relief in 30 days & Improved Quality of life in women with Iron Deficiency Anemia

Anemia continues to be a public health issue around the world, with some of the highest prevalence rates in Southeast Asia. Furthermore, it is a health risk that disproportionately affects some of our most vulnerable segments of society – women and children. Iron Deficiency Anemia (IDA) is the most prevalent type of Anemia, impacting up to 1 in 4 people in some countries across Southeast Asia with symptoms such as tiredness, dizziness and headaches affecting their quality of life and productivity.

Findings of the new SANOIN clinical study, supported by P&G Health (the healthcare division of P&G) and conducted by leading healthcare experts, demonstrated the efficacy of iron supplementation with Sangobion (ferrous gluconate + multivitamin & minerals) in improving Hemoglobin (Hb) levels & quality of life (QOL) with demonstrated symptom relief. SANOIN clinical study findings showed significant rise in Hb levels in 14 days, symptom relief in 30 days & improved QOL in women with Iron Deficiency Anemia.

Dr. Narcisa Sonia Comia, Hematologist (Mary Mediatrix Medical Center, Philippines) and Principal Investigator for SANOIN shared, "We conducted the SANOIN Clinical Non-Interventional Study with 97 women aged 15-55 years suffering from mild to moderate IDA across 6 hospitals in Philippines. Patients were administered Sangobion (ferrous gluconate plus multivitamin & minerals) over a 90-day period. We observed rapid Hemoglobin increase by 1.0 g/dL in 14 days which continued increasing by Day 90. Further, a 3.7x increase was observed in Serum ferritin levels which indicate the amount of iron stores in the body. Symptoms such as tiredness, dizziness and headache reduced significantly in as early as 30 days, with patients reporting an overall improvement in quality of life."

According to Dr. Christopher J. L. Soriano, Obstetrician and Gynaecologist (Ateneo de Manila University School of Medicine and Public Health, Philippines) and Co-Principal Investigator for SANOIN, "Estimates show that Indonesia has an iron deficiency anemia prevalence of 25-30%, while in the Philippines, IDA affects 1 in 4 pregnant women. In Malaysia, an estimated 31.6-34.6% of pregnant women are suffering from IDA. We are encouraged by the SANOIN clinical study results which highlight the role and impact of Iron Supplementation in treatment protocols and provides a safe and effective option for Filipino women to improve health outcomes to better care for themselves, their children and family. We look forward to sharing the findings of the study with healthcare practitioners from across South-East Asia and be deliberate on approaches to combat the growing burden of the disease."

Ian Barton, Senior Director, R&D Medical & Technical Affairs – P&G Health (Asia Pacific, India, Middle East & Africa) stated "P&G Health has been working on improving awareness and diagnoses of Iron Deficiency Anemia across Southeast Asia in collaboration with healthcare practitioners and associations. The New SANOIN Clinical study is another step in our commitment to support the fight against IDA. Through real-world evidence and clinical insights, the SANOIN clinical study highlights the role of iron supplementation in improving treatment outcomes and empowering consumers to live healthier and more vibrant lives. We would like to thank our esteemed panel of investigators and the women who participated in SANOIN. We are grateful to the International Pharmaceutical Federation (FIP) for including the SANOIN study findings in their recently published Pharmacists Handbook on managing IDA."

Disclaimer: Indications of Sangobion may differ in different countries, please check with your local healthcare professionals for more information.

About P&G Health:

P&G Health, the health care division of Procter & Gamble, drives consumer-centric innovation to empower our consumers to live healthier, and more vibrant lives.

New Study Publication Demonstrates Eye Health and Cognitive Benefits of Lutein and Zeaxanthin from Lutemax Kids

Six in ten parents regularly worry about their child's eye health, prioritizing it above other well-being needs; however, they are unfamiliar with ways to support it. This finding is according to a OmniActive Health Technologies U.S. parent survey for its "Lutein for Every Age" educational initiative, which focuses on raising awareness of early and consistent lutein and zeaxanthin intake to help support eye, cognitive, and general health throughout life.

OmniActive today unveils groundbreaking results from a first-of-its-kind completed supplementation study targeting children 5-12 years of age, which was published in the journal Advances in Therapy. The publication revealed that Lutemax Kids resulted in significant improvements in aspects of vision performance and cognition. This further expands upon the company's earlier published research on adults, including the LAMA I & LAMA II (Lutein, Vision and Mental Acuity), and B.L.U.E. (Blue Light User Exposure)  studies.

"The study results demonstrated that Lutemax Kids supplementation contributes positively to aspects of eye health and cognitive performance in school-aged children, echoing the well-documented benefits observed in adults," said Dr. Billy Hammond, Professor (Behavioral and Brain Sciences Program) at the University of Georgia and lead researcher in the study. "From improved visual processing speed to eye strain that may result from digital device use, these outcomes serve as a foundation for tailored supplementation in children. It also emphasizes the potential to help meet specific needs of children during a critical developmental phase."

Effects of Lutein and Zeaxanthin on Children's Eyes and Cognition

The randomized, double-blind, placebo-controlled trial which spanned 180-day duration included 60 healthy male and female children ages 5-12. Participants were given either a daily dose of Lutemax Kids, containing 10 mg lutein and 2 mg zeaxanthin isomers in a gummy format, or placebo.

The outcomes of the study supports that over time, supplementation with Lutemax Kids:

Significantly increased blood levels of lutein and zeaxanthin

Increased macular pigment optical density (MPOD) levels

Increased visual processing speed

Decreased eye strain and fatigue attributed to digital device usage

Significantly improved aspects of cognitive health, including attention, focus, episodic memory, visuospatial memory, and visuospatial processing speed

"Considering the amount of time kids are spending on screens, building a strong foundation for eye health through nutrition and supplementation from a young age is an important facet of maintaining a lifetime of well-being," said Dr. Joseph Allen, O.D., F.A.A.O., Dipl ABO and Vision Advisor for OmniActive's Lutein for Every Age. "This study is an important milestone for eye health and cognitive science, laying the groundwork for further understanding on how lutein and zeaxanthin can impact younger populations. It's exciting to see how nutrition can contribute positively to school-age children's eye health and cognitive performance."

Opportunity to Raise Nutrition Awareness 

It has been documented that only 1 in 11 U.S. children eat the recommended servings of fruits and vegetables per day. And since the body cannot produce lutein and zeaxanthin, two major carotenoids found in the eye's macula, it is important to consume these nutrients through foods, such as kale and spinach, or by supplementing.

To dig deeper into this topic for Lutein for Every Age, OmniActive's U.S. parent survey also suggests nutrition knowledge gaps around children's eye health. It was found that parents believe carrots are the best food to support vision (15%) when the American Academy of Ophthalmology (A.A.O.) recommends dark leafy greens because of the higher concentration of lutein. Unfortunately, only one in ten parents say their children take a vitamin or supplement daily.

Lutemax Kids, a line extension of OmniActive's pioneering lutein and zeaxanthin extract brand Lutemax 2020, is a lower dose to help meet the nutritional needs of children. To learn more about how to support eye and brain health visit Lutemax.com/lfea and to find supplements that feature the Lutemax ingredient, visit Lutemax.com/where-to-buy.

About OmniActive

Established in 2005, OmniActive seeks to improve lives through innovative science and natural health solutions. OmniActive's product portfolio consists of scientifically validated, IP-protected, branded Specialty Actives and an extensive portfolio of natural Botanical Actives for global customers in the dietary supplement, functional food, and beverage markets. The company has offices in Mumbai, India, and Bridgewater, New Jersey.

Gnosis Introduces Ethically Sourced Natural Energy & Mood Innovation: LANDKIND® Pure Salidroside

Building on 170 years of fermentation expertise, Gnosis enhances its portfolio with a natural ingredient for sport and mood segments produced ethically and sustainably.

A key global player in fermentation-derived ingredients, Gnosis by Lesaffre expands its presence in the sports and mood category with a unique ingredient that addresses the demand for natural energy solutions: LANDKIND® Pure Salidroside.

What is LANDKIND® Pure Salidroside?

Rhodiola (rosea or crenulata), known for its impact on energy levels, mood, and mental performance, has been a botanical used in natural products for decades. Rhodiola extracts typically contain 2 main actives—Rosavins and Salidroside. 

However, Salidroside is the most studied bioactive found in Rhodiola rosea or Rhodiola crenulata, with more than 680 scientific papers on Pubmed (vs 23 for Rosavin). With this new ingredient, Gnosis isolates Pure Salidroside through a proprietary fermentation process, delivering what José Luis Pinedo Rivera, the company’s Product Manager, New Molecules, considers “the best Rhodiola has to offer.”

“Crafted by fermentation, we only produce the best bioactive of the botanical in a pure form without the possible trace amounts of heavy metals, pesticides, and residual solvents that may be found in natural plant extracts,” explains Pinedo Rivera. “Our LANDKIND® Pure Salidroside is a bioengineered compound, whose safety is ensured by toxicological studies, with supporting clinical data.”

The results of a clinical study show that supplementation with Salidroside may be an effective way to enhance oxygen uptake during graded exercise. Additionally, it has the potential to mitigate performance decline associated with accumulated fatigue and mitigate mood disturbance, particularly related to fatigue and friendliness. The study findings will soon be available for publication.

LANDKIND® Pure Salidroside offers a high-quality source of the best of Rhodiola with consistent purity and premium features:

• Quality: 98% pure Salidroside

• Low Dosage: 60mg/day (suggested dosage based on the clinical study)

• Suitable Diets: Halal, Vegan-friendly, and Gluten-free

• Self-affirmed GRAS 

How Is LANDKIND® Pure Salidroside Emblematic of Gnosis’ Mission?

Found naturally in high altitudes in Europe and Asia and taking more than 20 years to mature, the increasing demand for Rhodiola rosea became the main threat of overharvesting it. Thus, developing ecological ways to harness the benefits of Rhodiola has become a key step in preserving this species.

To ensure its sustainable harvest and trade, Rhodiola was added to the CITES (Convention on International Trade in Endangered Species of Wild Fauna and Flora) list of endangered species.  Therefore, LANDKIND® Pure Salidroside’s innovative fermentation process bypasses the need to harvest Rhodiola rosea, offering a sustainable source of this botanical in the form of Pure Salidroside—sustainable and CITES-compliant by design.

Gnosis’s parent company Lesaffre is committed to investing in fermentation platforms in the United States and Europe to strengthen the company’s fermentation expertise to deliver naturally derived molecules that benefit human health while enhancing its sustainability commitment. 

“At Gnosis, we believe in exploring life to improve living, which is why our natural ingredient solutions are all based on fermentation,” says Damien Zanalda, Gnosis by Lesaffre Global Sales Director. “The groundbreaking fermentation process for LANDKIND® Pure Salidroside is even more critical because it bypasses the need to harvest an endangered species. Rather, we can extract the best of Rhodiola with consistent purity. 

“Most importantly, it offers brand owners a unique position,” Zanalda adds. “Our LANDKIND® Pure Salidroside requires a lower dose versus Rhodiola extracts, which is much more convenient for formulators, leaving space in the product for other bioactives. Our partners can use our targeted bioactive to provide a natural energy component to their existing products or use it as a base for their natural energy innovation.” 

Gnosis by Lesaffre will officially introduce LANDKIND® Pure Salidroside at Natural Products Expo West in March.

About Gnosis by Lesaffre 

Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and well-being. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers. 

Gnosis by Lesaffre – Exploring Life to Improve Living. http://www.GnosisByLesaffre.com

About Lesaffre 

A key global player in fermentation for more than a century, Lesaffre, with a 2,7 billion euro turnover, and established on all continents, counts 11,000 employees and more than 90 nationalities. On the strength of this experience and diversity, we work with customers, partners, and researchers to find ever more relevant answers to the needs of food, health, naturalness, and respect for our environment. Thus, every day, we explore and reveal the infinite potential of microorganisms.

To nourish 9 billion people, in a healthy way, in 2050 by making the most of our planet’s resources is a major and unprecedented issue. We believe that fermentation is one of the most promising answers to this challenge.

Lesaffre – Working together to better nourish and protect the planet. www.lesaffre.com